[A20-35] Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

Last updated 01.10.2020

Project no.:

Commission awarded on 31.03.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Adults with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies

Result of dossier assessment:

In case of 2 prior regimens: hint of greater harm due to side effects. In case of more than 2 prior therapies, due to major survival advantage and analogue side effects: hint of minor added benefit.


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Current document

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Federal Joint Committee (G-BA)

2020-10-01 A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.